TRASTUZUMAB MOA SECRETS

Among the most beneath-investigated “driving forces” associated with trastuzumab resistance is PTEN. Nagata et al. (2004) reported that the lack of PTEN was observed in 36% of HER2-good Main breast tumor specimens from sufferers with phase IV disorder. Additionally, In addition they showed that patients with PTEN-deficient tumors had remarkably